J&J

Showing 15 posts of 227 posts found.

J&J’s Invokana becomes first FDA-approved oral diabetes drug to reduce cardiovascular event risk

October 31, 2018
Research and Development, Sales and Marketing FDA, J&J, JJ, invokana, pharma

The FDA has given the go-ahead for Johnson & Johnson’s drug Invokana (canagliflozin) for use in the risk reduction of …

US court overturns J&J’s Zytiga patent in combination with prednisone

October 29, 2018
Sales and Marketing J&J, JJ, Johnson and Johnson, Zytiga, court, generic, prednisone

A court in New Jersey has invalidated Johnson & Johnson’s patent on the prostate cancer drug Zytiga when used in …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

October 26, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, GSK, HDA, J&J, JJ, brexit, clinical trials, pharmafile, resutls, stockpiling, top 10

Winter is coming! And with it an assortment of promising and not so promising results from big pharma. While J&J …

J&J announce promising Phase 1/2a results for HIV vaccine

October 23, 2018
Manufacturing and Production AIDS, HIV, J&J, JJ, Vaccine, infectious diseases

The world may be one step closer to discovering a preventative vaccine for HIV following American multinational Johnson & Johnson’s …

GSK named third best UK workplace

October 22, 2018
Sales and Marketing AbbVie, Amgen, BMS, Eli Lilly, GSK, J&J, JJ, work

British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs …

jj_sign_on_wall

J&J pledges to end global TB pandemic

September 25, 2018
Manufacturing and Production J&J, JJ, Johnson and Johnson, TB, access, tuberculosis

Johnson and Johnson have announced that they are launching a 10-year initiative aimed at helping to end tuberculosis, the world’s …

janssen_latest_logo_on_sign

Europe approves Janssen’s Darzalex in frontline multiple myeloma

September 4, 2018
Manufacturing and Production, Research and Development, Sales and Marketing EU, Europe, J&J, JJ, Janssen, darzalex, multiple myeloma, pharma

Janssen has revealed that its CD38-targeting biologic drug Darzalex (daratumumab) has received approval from the European Commission, authorising its use …

pharmafocus_oct_2018

The September 2018 issue of Pharmafocus is available to read online now!

September 3, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, AstraZeneca, Cancer, Iraw, J&J, JJ, Pfizer, Roche, UK, brexit, drug safety, pharma, pharmacovigilance

The new September edition of Pharmafocus is now live and available to read online. We’re entering the final stretch as …

nhs_sign

NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients

August 10, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma

The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …

usmarinetankinbaghdad

Lawsuit alleges pharma giants funded terror in Iraq

August 2, 2018
Business Services, Medical Communications, Sales and Marketing AstraZeneca, Iraq War, J&J, JJ, Litigation, Roche, corruption, terrorism

The United States Justice Department is investigating claims that major pharmaceutical and medical device companies were aware that supplies that …

top_10_image

Top Ten most popular articles on Pharmafile.com this week

July 20, 2018
Medical Communications GSK, ICR, J&J, JJ, Novartis, Trump, brexit, top 10

As Brexit negotions have hit a stalemate this week, the United Kingdom’s exit from the European Union has hit the …

jj_sign_on_wall

J&J stops Invokana trial early after success in kidney disease and type 2 diabetes

July 17, 2018
Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes

Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …

johnson_and_johnson_jj

J&J ordered to pay $4.68 billion to talc-powder plaintiffs

July 13, 2018
Medical Communications J&J, JJ, Johnson and Johnson, legal, talc powder

A Missouri jury has ordered the New Jersey-based healthcare company Johnson and Johnson to pay $4.69 billion to 22 women …

Missouri appeals court overturns $55m J&J verdict

July 6, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Litigation, appeal, pharma

A $55 million verdict against the multinational pharmaceutical company Johnson & Johnson has been overturned by an appeals court in …

The Gateway to Local Adoption Series

Latest content